Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An update on ovarian suppression/ablation.

R Jakesz1

  • 1Division of General Surgery, Vienna Medical School, Vienna, Austria. raimund.jakesz@meduniwien.ac.at

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|October 3, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.

Breast (Edinburgh, Scotland)·2019
Same author

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2- early breast cancer.

British journal of cancer·2014
Same author

Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24).

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same journal

Corrigendum to "Joint GOG-Foundation (GOG) and European Network of Gynaecological Oncological Trial Groups (ENGOT) clinical trials guidance for operations with industry partners" [International Journal of Gynecological Cancer 36 (2026) 104753].

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

piR-hsa-8111406 promotes proliferation and serves as a novel biomarker for early detection of ovarian cancer: a multi-center retrospective study.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Poly(adenosine diphosphate-ribose) polymerase inhibitor maintenance therapy with niraparib in patients with primary advanced or recurrent endometrial cancer receiving dostarlimab plus chemotherapy.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Balancing fertility potential and oncologic and obstetric risks: a vignette study on decision-making in fertility-sparing surgery for early-stage cervical cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

Updated pocket guide for integrated risk stratification in endometrial carcinoma: a practical tool based on European Society of Gynecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology 2025 guidelines.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same journal

How long is enough? Immunotherapy duration in mismatch repair deficient endometrial cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
See all related articles

Adjuvant ovarian function suppression using goserelin and tamoxifen is an effective alternative to chemotherapy for premenopausal women with early breast cancer. This therapy reduces recurrence risk in estrogen receptor-positive patients.

Area of Science:

  • Oncology
  • Endocrinology
  • Pharmacology

Background:

  • Adjuvant ovarian function suppression is a recognized therapy for premenopausal early breast cancer.
  • Ovarian ablation via surgery or irradiation has been compared to chemotherapy with similar disease-free survival (DFS) outcomes.
  • Luteinizing hormone-releasing hormone analogues (LHRHa) offer medical ovarian suppression, avoiding surgical morbidity.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of LHRHa, specifically goserelin, in premenopausal breast cancer patients.
  • To compare LHRHa-based therapies with chemotherapy and assess the role of tamoxifen.
  • To determine if combined goserelin and tamoxifen is a viable alternative to chemotherapy.

Main Methods:

  • Review of prospective randomized trials and multiple-arm studies.

Related Experiment Videos

  • Analysis of treatment outcomes comparing LHRHa (goselin) with or without tamoxifen against chemotherapy.
  • Evaluation of DFS rates and patient tolerability in different treatment arms.

    • Main Results:

    • Goserelin (or other LHRHa) combined with tamoxifen demonstrated improved DFS and better tolerability in hormone-responsive patients.
    • Addition of tamoxifen to goserelin plus chemotherapy improved DFS.
    • Significant benefits were observed in goserelin-treated patients, regardless of chemotherapy or tamoxifen use.

    Conclusions:

    • Combined ovarian suppression with adjuvant goserelin and tamoxifen is as effective as chemotherapy for premenopausal breast cancer.
    • Ovarian suppression is a safe method for reducing recurrence risk in estrogen receptor-positive women.
    • LHRHa therapy represents a competitive alternative to chemotherapy in this patient population.